Bank of America
SAGE

Bank of America’s Sage Therapeutics SAGE Stock Holding History

Bank of America’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,000
Closed -$1.41M – 7921
2023
Q2 		$1.41M Buy
+30,000
New +$1.49M ﹤0.01% 4516
2020
Q1 		– Sell
-13,000
Closed -$938K – 7191
2019
Q4 		$938K Buy
+13,000
New +$1.6M ﹤0.01% 4552
2018
Q1 		– Sell
-262,400
Closed -$43.2M – 7310
2017
Q4 		$43.2M Buy
262,400
+206,900
+373% +$20.1M 0.01% 1195
2017
Q3 		$3.46M Buy
55,500
+5,500
+11% +$432K ﹤0.01% 3517
2017
Q2 		$3.98M Buy
+50,000
New +$3.61M ﹤0.01% 3252

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bank of America's SAGE Position: Q3 2025 in Review

Bank of America sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 145,799 shares — an estimated $1.33M sold.

Bank of America first reported a position in SAGE in Q4 2014 and held it in 43 quarters. The position peaked at $44.7M in Q1 2019. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Bank of America reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank of America sold 145,799 Sage Therapeutics shares in Q3 2025, an estimated $1.33M.
  • Bank of America first reported a position in Sage Therapeutics in Q4 2014 and held it in 43 quarters.
  • Bank of America's Sage Therapeutics position peaked at $44.7M in Q1 2019.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.